These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568 [TBL] [Abstract][Full Text] [Related]
4. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. Sheehy SH; Duncan CJ; Elias SC; Biswas S; Collins KA; O'Hara GA; Halstead FD; Ewer KJ; Mahungu T; Spencer AJ; Miura K; Poulton ID; Dicks MD; Edwards NJ; Berrie E; Moyle S; Colloca S; Cortese R; Gantlett K; Long CA; Lawrie AM; Gilbert SC; Doherty T; Nicosia A; Hill AV; Draper SJ PLoS One; 2012; 7(2):e31208. PubMed ID: 22363582 [TBL] [Abstract][Full Text] [Related]
5. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237 [TBL] [Abstract][Full Text] [Related]
6. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J; Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358 [TBL] [Abstract][Full Text] [Related]
7. Liver-Directed AAV8 Booster Vaccine Expressing Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S Front Immunol; 2021; 12():612910. PubMed ID: 34248928 [TBL] [Abstract][Full Text] [Related]
8. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232 [TBL] [Abstract][Full Text] [Related]
9. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine. Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267 [TBL] [Abstract][Full Text] [Related]
10. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal. Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B; PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537 [TBL] [Abstract][Full Text] [Related]
11. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197 [TBL] [Abstract][Full Text] [Related]
13. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model. Dunachie S; Berthoud T; Hill AV; Fletcher HA Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
15. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620 [TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Walther M; Thompson FM; Dunachie S; Keating S; Todryk S; Berthoud T; Andrews L; Andersen RF; Moore A; Gilbert SC; Poulton I; Dubovsky F; Tierney E; Correa S; Huntcooke A; Butcher G; Williams J; Sinden RE; Hill AV Infect Immun; 2006 May; 74(5):2706-16. PubMed ID: 16622207 [TBL] [Abstract][Full Text] [Related]